Leading medical societies warn that proposed changes and funding delays at the National Institutes of Health could disrupt active studies and patient care.
RT’s Three Key Takeaways:
- Federal Restructuring Concerns: The National Institutes of Health announced a proposed overhaul of clinical research programs at the National Institute of Allergy and Infectious Diseases with limited details and an abbreviated public comment window, according to medical leaders.
- Risks to Clinical Trials: Prolonged delays in federal funding renewals threaten active research networks and centers investigating HIV, tuberculosis, and viral hepatitis, placing study participants at risk.
- Urgent Call for Oversight: Healthcare groups are petitioning federal leaders to release funding opportunities immediately and requesting congressional oversight to prevent the disruption of long-standing biomedical research investments.
A proposed federal plan to restructure infectious disease clinical research has drawn sharp criticism from healthcare leaders, who warn that the move could jeopardize ongoing clinical trials and compromise the response of the US to critical public health threats.
The Infectious Diseases Society of America (IDSA) and the HIV Medicine Association (HIVMA) expressed concern regarding an Aug 28 notice released by the National Institutes of Health (NIH) detailing a planned overhaul of the clinical research portfolio at the National Institute of Allergy and Infectious Diseases (NIAID). According to the organizations, the announcement provided few details and allowed only a brief comment period.
“Changes of the magnitude suggested deserve a lengthier and meaningful opportunity for input from researchers, clinicians, community partners and other stakeholders including Congress,” said Ronald G Nahass, MD, president of IDSA, in a news release.
Delays Threaten Research Infrastructure
The restructuring announcement follows months of administrative delays by the NIH in releasing renewal notices for NIAID clinical trial networks as well as the Centers for AIDS Research (CFARs), according to the societies. While renewal notices for infectious disease networks were released the first week of September, notices for the CFARs and HIV clinical trial networks remain delayed.
The medical associations stated that destabilizing the research infrastructure will directly harm enrolled trial participants and weaken the ability of the nation to respond to infectious diseases. The groups noted that these disruptions arrive as healthcare workforce shortages in infectious diseases continue to worsen and front-line public healthcare systems experience ongoing strain from staffing shortages and funding reductions.
Broader Impact on Infectious Disease Discoveries
According to IDSA and HIVMA, the research infrastructure developed by NIAID has produced discoveries that have saved millions of lives globally. In addition to HIV management, the networks have contributed to key therapies for comorbid and infectious conditions, including viral hepatitis and tuberculosis (TB), which remains the deadliest infectious disease in the world.
Specific medical advances attributed to these networks include:
- The development of HIV antiretroviral therapies that suppress viral loads to undetectable levels and demonstrate 99% efficacy in preventing HIV transmission,
- Foundational research enabling curative treatments for hepatitis C, and
- The establishment of shorter clinical treatment regimens for TB.
Petitions for Administrative and Congressional Action
The leadership of IDSA and HIVMA stated that federal agencies must protect ongoing clinical trials and ensure continuity for participants currently enrolled in studies.
“We call on NIH to prioritize the health and biosecurity of Americans by immediately releasing the HIV clinical research networks and centers notices of funding opportunities, providing extensions where needed to protect study participants and ensure research in clinical trials underway is not lost,” said Anna K Person, MD, chair of HIVMA, in a news release.
The organizations also called on Congress to initiate oversight proceedings to prevent the dismantling of decades of federal investments in national biomedical research infrastructure.
